- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Psoriasis survey reveals discrimination and low treatment expectations
29 June 2016 • Author: Victoria White, Digital Content Producer
Findings from the largest global survey to date of people with psoriasis reveal 84% of people with moderate-to-severe psoriasis suffer discrimination and humiliation, with many being stared at in public as a result of their medical condition.
In addition, the results from more than 8,300 participants show that people with psoriasis have very low treatment expectations of achieving clear skin.
Novartis initiated and funded the survey. Vasant Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis, commented: “This survey marks our commitment to support the World Health Organization’s (WHO) resolution to make psoriasis a global health priority, fighting the stigma and ignorance associated with psoriasis and advancing patient care.”
Over 8,300 people from 31 countries took part in the survey, and it is also the first of its kind to explore perceptions of clear skin in psoriasis. This is the largest ever partnership between Novartis and patient organisations, including 25 groups from around the world.
55% don’t believe clear skin is a realistic goal
Along with unacceptable levels of discrimination and humiliation, the survey shows that nearly half of people with psoriasis have been asked if they are contagious. The devastating effect psoriasis can have on personal lives and people’s mental health was also revealed, with the survey showing 16% of people admit to hiding themselves away from the world as a coping mechanism. This lack of hope and self-esteem is reflected in the results, with 55% of people stating they do not believe clear or almost clear skin is a realistic goal for them.
“Everyone deserves the right to receive effective treatment for their psoriasis and work towards the goal of clear skin, but this survey shows the majority of people simply don’t think it’s possible,” said Dr Richard B Warren, Reader Lecturer and Honorary Consultant Dermatologist at the Dermatology Centre Salford Royal Foundation Hospital, University of Manchester. “Though we may not be able to change the public’s attitude overnight, as dermatologists, we should work with patients to encourage them to strive towards a treatment goal of clear skin.”
Further survey results can be found on www.skintolivein.com. Novartis worked with artist, Natalie Fletcher, to bring the hopes and stories of survey participants to life through a series of body painting. You can watch the though-provoking video below:
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics